Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Statistical analysis of single-copy assays when some observations are zero.

Bacchetti P, Bosch RJ, Scully EP, Deng X, Busch MP, Deeks SG, Lewin SR.

J Virus Erad. 2019 Sep 18;5(3):167-173.

PMID:
31700666
2.

Statistical analysis of single-copy assays when some observations are zero.

Bacchetti P, Bosch RJ, Scully EP, Deng X, Busch MP, Deeks SG, Lewin SR.

J Virus Erad. 2019 Sep 18;5(3):167-173.

PMID:
31700665
3.

Tesamorelin, liver fat, and NAFLD in the setting of HIV.

Audsley J, Sasadeusz J, Lewin SR.

Lancet HIV. 2019 Oct 11. pii: S2352-3018(19)30331-5. doi: 10.1016/S2352-3018(19)30331-5. [Epub ahead of print] No abstract available.

PMID:
31611037
4.

Community and provider Community and provider perspectives on Treatment Interruptions in the landscape of HIV cure focused studies.

Lau J, Smith MZ, Allan B, Martinez C, Power J, Lewin SR, McMahon JH.

AIDS Res Hum Retroviruses. 2019 Oct 14. doi: 10.1089/AID.2019.0118. [Epub ahead of print]

PMID:
31608648
5.

CD4+ T cell signatures in HIV infection.

Gubser C, Pitman MC, Lewin SR.

Nat Immunol. 2019 Aug;20(8):948-950. doi: 10.1038/s41590-019-0447-5. No abstract available.

PMID:
31308542
6.

TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.

Natesampillai S, Paim AC, Cummins NW, Chandrasekar AP, Bren GD, Lewin SR, Kiem HP, Badley AD.

J Immunol. 2019 Aug 1;203(3):718-724. doi: 10.4049/jimmunol.1900271. Epub 2019 Jun 12.

PMID:
31189571
7.

Between a shock and a hard place: challenges and developments in HIV latency reversal.

Zerbato JM, Purves HV, Lewin SR, Rasmussen TA.

Curr Opin Virol. 2019 Oct;38:1-9. doi: 10.1016/j.coviro.2019.03.004. Epub 2019 Apr 29. Review.

PMID:
31048093
8.

A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries.

Kapoor N, Audsley J, Rupali P, Sasadeusz J, Paul TV, Thomas N, Lewin SR.

AIDS. 2019 Jun 1;33(7):1105-1115. doi: 10.1097/QAD.0000000000002161.

PMID:
31045941
9.

Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models.

Nguyen W, Jacobson J, Jarman KE, Jousset Sabroux H, Harty L, McMahon J, Lewin SR, Purcell DF, Sleebs BE.

J Med Chem. 2019 May 23;62(10):5148-5175. doi: 10.1021/acs.jmedchem.9b00462. Epub 2019 Apr 29.

PMID:
30973727
10.

Reducing the gap between the diagnosis and treatment of HIV infection.

Singh KP, Lewin SR.

Med J Aust. 2019 Apr;210(6):261-262. doi: 10.5694/mja2.50114. No abstract available.

PMID:
30929277
11.

Clinical trials of antiretroviral treatment interruption in HIV-infected individuals.

Lau JSY, Smith MZ, Lewin SR, McMahon JH.

AIDS. 2019 Apr 1;33(5):773-791. doi: 10.1097/QAD.0000000000002113.

PMID:
30883388
12.

Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models.

Juno JA, Wragg KM, Kristensen AB, Lee WS, Selva KJ, van der Sluis RM, Kelleher AD, Bavinton BR, Grulich AE, Lewin SR, Kent SJ, Parsons MS.

J Virol. 2019 May 15;93(11). pii: e00242-19. doi: 10.1128/JVI.00242-19. Print 2019 Jun 1.

PMID:
30867307
13.

CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Lee WS, Prévost J, Richard J, van der Sluis RM, Lewin SR, Pazgier M, Finzi A, Parsons MS, Kent SJ.

J Virol. 2019 May 1;93(10). pii: e01901-18. doi: 10.1128/JVI.01901-18. Print 2019 May 15.

14.

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals.

Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sékaly RP, Chomont N.

Nat Commun. 2019 Feb 18;10(1):814. doi: 10.1038/s41467-019-08798-7.

15.

2018 international meeting of the Global Virus Network.

Brechot C, Bryant J, Endtz H, Garry RF, Griffin DE, Lewin SR, Mercer N, Osterhaus A, Picot V, Vahlne A, Verjans GMGM, Weaver S.

Antiviral Res. 2019 Mar;163:140-148. doi: 10.1016/j.antiviral.2019.01.013. Epub 2019 Jan 25. Review.

PMID:
30690044
16.

Circulating BAFF and CXCL10 levels predict response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B.

Khlaiphuengsin A, Chuaypen N, Hirankarn N, Avihingsanon A, Crane M, Lewin SR, Tangkijvanich P.

Asian Pac J Allergy Immunol. 2019 Jan 13. doi: 10.12932/AP-050718-0365. [Epub ahead of print]

17.

Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome Is Associated With Dysregulation of IL-7/IL-7 Receptor Signaling Pathway in T Cells and Monocyte Activation.

Akilimali NA, Muema DM, Specht C, Chang CC, Moosa MS, Levitz SM, Lewin SR, French MA, Ndungʼu T.

J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):596-604. doi: 10.1097/QAI.0000000000001946.

PMID:
30649031
18.

HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal.

Moso MA, Anderson JL, Adikari S, Gray LR, Khoury G, Chang JJ, Jacobson JC, Ellett AM, Cheng WJ, Saleh S, Zaunders JJ, Purcell DFJ, Cameron PU, Churchill MJ, Lewin SR, Lu HK.

AIDS. 2019 Feb 1;33(2):199-209. doi: 10.1097/QAD.0000000000002075.

PMID:
30562171
19.

Combination treatment prevents HIV re-emergence in monkeys.

Lewin SR.

Nature. 2018 Nov;563(7731):333-335. doi: 10.1038/d41586-018-06818-y. No abstract available.

PMID:
30425354
20.

Functional cure of HIV: the scale of the challenge.

Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent SJ.

Nat Rev Immunol. 2019 Jan;19(1):45-54. doi: 10.1038/s41577-018-0085-4.

PMID:
30410126
21.

PD-1 Expression in HIV-Specific CD8+ T cells Before Antiretroviral Therapy Is Associated With HIV Persistence.

Ghiglione Y, Trifone C, Salido J, Rhodes A, Ruiz MJ, Polo ML, Salomón H, Laufer N, Sued O, Lewin SR, Turk G.

J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):1-6. doi: 10.1097/QAI.0000000000001887.

PMID:
30399040
22.

Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.

Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A, Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M, Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG.

J Infect Dis. 2019 Mar 15;219(7):1084-1094. doi: 10.1093/infdis/jiy617.

PMID:
30371873
23.

Strategies for an HIV cure: progress and challenges.

Wang FS, Zhang L, Douek D, McMichael A, Xu XN, Lewin SR.

Nat Immunol. 2018 Nov;19(11):1155-1158. doi: 10.1038/s41590-018-0242-8. No abstract available.

PMID:
30333614
24.

Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals.

Lee SC, Chua LL, Yap SH, Khang TF, Leng CY, Raja Azwa RI, Lewin SR, Kamarulzaman A, Woo YL, Lim YAL, Loke P, Rajasuriar R.

Sci Rep. 2018 Sep 24;8(1):14277. doi: 10.1038/s41598-018-32585-x.

25.

Perceptions of HIV cure research among people living with HIV in Australia.

Power J, Westle A, Dowsett GW, Lucke J, Tucker JD, Sugarman J, Lewin SR, Hill S, Brown G, Wallace J, Richmond J.

PLoS One. 2018 Aug 24;13(8):e0202647. doi: 10.1371/journal.pone.0202647. eCollection 2018.

26.

Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial.

Lee SA, Elliott JH, McMahon J, Hartogenesis W, Bumpus NN, Lifson JD, Gorelick RJ, Bacchetti P, Deeks SG, Lewin SR, Savic RM.

Clin Pharmacol Ther. 2019 Mar;105(3):692-702. doi: 10.1002/cpt.1220. Epub 2018 Oct 9.

PMID:
30137649
27.

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C.

Lancet. 2018 Jul 28;392(10144):312-358. doi: 10.1016/S0140-6736(18)31070-5. Epub 2018 Jul 20. Review. No abstract available.

28.

Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+ T Cells.

Kumar NA, van der Sluis RM, Mota T, Pascoe R, Evans VA, Lewin SR, Cameron PU.

J Immunol. 2018 Sep 1;201(5):1468-1477. doi: 10.4049/jimmunol.1701233. Epub 2018 Jul 20.

29.

Association Between Plasma Antibody Responses and Risk for Cryptococcus-Associated Immune Reconstitution Inflammatory Syndrome.

Yoon HA, Nakouzi A, Chang CC, Kuniholm MH, Carreño LJ, Wang T, Ndung'u T, Lewin SR, French MA, Pirofski LA.

J Infect Dis. 2019 Jan 9;219(3):420-428. doi: 10.1093/infdis/jiy447.

PMID:
30010905
30.

Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1.

Chang CC, Naranbhai V, Stern J, Roche M, Dantanarayana A, Ke R, Tennakoon S, Solomon A, Hoh R, Hartogensis W, Hecht FM, Sikaris K, Price DJ, Elliott JH, Deeks SG, Churchill M, Cameron PU, Hengartner N, Perelson AS, Lewin SR.

AIDS. 2018 Sep 24;32(15):2119-2128. doi: 10.1097/QAD.0000000000001937. Erratum in: AIDS. 2018 Nov 13;32(17):2643-2647.

31.

Barriers and strategies to achieve a cure for HIV.

Pitman MC, Lau JSY, McMahon JH, Lewin SR.

Lancet HIV. 2018 Jun;5(6):e317-e328. doi: 10.1016/S2352-3018(18)30039-0. Review.

32.

HIV latency reversing agents act through Tat post translational modifications.

Khoury G, Mota TM, Li S, Tumpach C, Lee MY, Jacobson J, Harty L, Anderson JL, Lewin SR, Purcell DFJ.

Retrovirology. 2018 May 11;15(1):36. doi: 10.1186/s12977-018-0421-6.

33.

Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency.

Evans VA, van der Sluis RM, Solomon A, Dantanarayana A, McNeil C, Garsia R, Palmer S, Fromentin R, Chomont N, Sékaly RP, Cameron PU, Lewin SR.

AIDS. 2018 Jul 17;32(11):1491-1497. doi: 10.1097/QAD.0000000000001849.

34.

Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants.

Sojane K, Kangethe RT, Chang CC, Moosa MS, Lewin SR, French MA, Ndung'u T.

AIDS Res Hum Retroviruses. 2018 Jul;34(7):607-620. doi: 10.1089/AID.2017.0209. Epub 2018 May 23.

35.

The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.

Rezaei SD, Lu HK, Chang JJ, Rhodes A, Lewin SR, Cameron PU.

J Virol. 2018 Jun 13;92(13). pii: e02225-17. doi: 10.1128/JVI.02225-17. Print 2018 Jul 1.

36.

The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.

Rasmussen TA, McMahon JH, Chang JJ, Audsley J, Rhodes A, Tennakoon S, Dantanarayana A, Spelman T, Schmidt T, Kent SJ, Morcilla V, Palmer S, Elliott JH, Lewin SR.

Lancet HIV. 2018 May;5(5):e221-e230. doi: 10.1016/S2352-3018(18)30040-7. Epub 2018 Apr 8.

PMID:
29643011
37.

Immune Monitoring for CMV in Transplantation.

Yong MK, Lewin SR, Manuel O.

Curr Infect Dis Rep. 2018 Mar 14;20(4):4. doi: 10.1007/s11908-018-0610-4. Review.

PMID:
29542023
38.

Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.

Kim Y, Anderson JL, Lewin SR.

Cell Host Microbe. 2018 Jan 10;23(1):14-26. doi: 10.1016/j.chom.2017.12.004. Review.

39.

Towards a cure for human immunodeficiency virus.

Pitman MC, Lewin SR.

Intern Med J. 2018 Jan;48(1):12-15. doi: 10.1111/imj.13673. No abstract available.

40.

HIV integration sites and implications for maintenance of the reservoir.

Symons J, Cameron PU, Lewin SR.

Curr Opin HIV AIDS. 2018 Mar;13(2):152-159. doi: 10.1097/COH.0000000000000438. Review.

41.

The end of HIV: Still a very long way to go, but progress continues.

Deeks SG, Lewin SR, Bekker LG.

PLoS Med. 2017 Nov 30;14(11):e1002466. doi: 10.1371/journal.pmed.1002466. eCollection 2017 Nov.

42.

Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

Yong MK, Cameron PU, Slavin MA, Cheng AC, Morrissey CO, Bergin K, Spencer A, Ritchie D, Lewin SR.

Front Immunol. 2017 Nov 9;8:1506. doi: 10.3389/fimmu.2017.01506. eCollection 2017.

43.

HIV cure research: print and online media reporting in Australia.

Power J, Fileborn B, Dowsett GW, Lucke J, Brown G, Ellard J, Lewin SR, Tucker JD, Slavin S, Sugarman J, Hill S.

J Virus Erad. 2017 Oct 1;3(4):229-235.

44.

Plasma But Not Cerebrospinal Fluid Interleukin 7 and Interleukin 5 Levels Pre-Antiretroviral Therapy Commencement Predict Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome.

Akilimali NA, Chang CC, Muema DM, Reddy T, Moosa MS, Lewin SR, French MA, Ndung'u T.

Clin Infect Dis. 2017 Oct 16;65(9):1551-1559. doi: 10.1093/cid/cix598.

45.

Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?

Cromer D, Pinkevych M, Rasmussen TA, Lewin SR, Kent SJ, Davenport MP.

J Virol. 2017 Nov 30;91(24). pii: e01395-17. doi: 10.1128/JVI.01395-17. Print 2017 Dec 15.

46.

Immune checkpoint blockade in infectious diseases.

Wykes MN, Lewin SR.

Nat Rev Immunol. 2018 Feb;18(2):91-104. doi: 10.1038/nri.2017.112. Epub 2017 Oct 9. Review.

47.

Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection.

Palmer CS, Duette GA, Wagner MCE, Henstridge DC, Saleh S, Pereira C, Zhou J, Simar D, Lewin SR, Ostrowski M, McCune JM, Crowe SM.

FEBS Lett. 2017 Oct;591(20):3319-3332. doi: 10.1002/1873-3468.12843. Epub 2017 Oct 11.

48.

Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring.

Yong MK, Ananda-Rajah M, Cameron PU, Morrissey CO, Spencer A, Ritchie D, Cheng AC, Lewin SR, Slavin M.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1961-1967. doi: 10.1016/j.bbmt.2017.07.025. Epub 2017 Aug 7.

49.

Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.

Flynn JK, Ellenberg P, Duncan R, Ellett A, Zhou J, Sterjovski J, Cashin K, Borm K, Gray LR, Lewis M, Jubb B, Westby M, Lee B, Lewin SR, Churchill M, Roche M, Gorry PR.

AIDS Res Hum Retroviruses. 2017 Dec;33(12):1220-1235. doi: 10.1089/AID.2017.0097. Epub 2017 Sep 26.

PMID:
28797170
50.

Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy.

To EE, Vlahos R, Luong R, Halls ML, Reading PC, King PT, Chan C, Drummond GR, Sobey CG, Broughton BRS, Starkey MR, van der Sluis R, Lewin SR, Bozinovski S, O'Neill LAJ, Quach T, Porter CJH, Brooks DA, O'Leary JJ, Selemidis S.

Nat Commun. 2017 Jul 12;8(1):69. doi: 10.1038/s41467-017-00057-x.

Supplemental Content

Loading ...
Support Center